drugset / Trial / NCT01310244
MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLC
NaSingle-groupOpen-labelTreatment
Summary
To define Phase 1/2 Maximum Tolerated Dose Study of Belinostat (PXD-101) in Combination with Paclitaxel plus Carboplatin in Chemotherapy-Naive Patients with Stage IV Non-Small-Cell Lung Cancer (NSCLC).
Timeline
- Start
- 2010-12
- Primary completion
- 2015-08
- Completion
- 2015-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Belinostat | Small molecule | 1000 mg/m2 | Intravenous |
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Paclitaxel | Small molecule | 200 mg/m2 | — |